Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pomaglumetad methionil

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

Allergan logo

More waiting for Allergan and Gedeon Richter’s antipsychotic

FDA announced it will take another three months to review cariprazine for schizophrenia

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Eli Lilly HQ

Lilly and Incyte’s baricitinib aces phase III trials

Supports its potential as a therapy for rheumatoid arthritis

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

Lilly backs Bluetooth insulin device and app firm

Invests in San Diego-based medical device company Companion Medical

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

FDA approves J&J’s schizophrenia drug Invega Trinza

New version of Invega is the first treatment for the condition to require only four doses a year

Eli Lilly HQ

Lilly and Sanford-Burnham reveal immunology collaboration

Will aim to discover and develop therapies in the field

Eli Lilly HQ

Lilly and BioNTech partner on cancer immunotherapy

Lilly gets on board with the hottest research ticket in town

- PMLiVE

Transition takes on Lilly muscle-boosting drug

Lilly to receive just $1m upfront but could get up to $100m in milestones

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links